INNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026

Stock News06-03

Shares of INNOGEN-B (02591) have risen more than 6%. At the time of writing, the stock is up 5.79% to HK$10.62, with a turnover of HK$90.33 million.

The company has announced that it will present data from the Chinese Phase IIb clinical study of its drug, Esupaglutide α, at the American Diabetes Association (ADA) Scientific Sessions in 2026. This conference is scheduled to take place from June 5 to 8, 2026, in New Orleans, USA.

According to the announcement, the top-line results from the Phase IIb ENLIGHT study of INNOGEN's self-developed Esupaglutide α in Chinese patients with overweight/obesity have successfully met the primary endpoint. The randomized, double-blind, placebo-controlled, multicenter trial enrolled 200 adult subjects with overweight or obesity but without diabetes. It evaluated the efficacy and safety of Esupaglutide α at doses ranging from 5 mg to 20 mg over an 18-week treatment period.

The results indicated that all dose groups experienced significant weight reduction from baseline, outperforming the placebo group. The weight loss effect showed a positive correlation with the dose, and patients in the Esupaglutide α groups demonstrated a continuous downward trend in body weight throughout the treatment period, with no plateau observed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162227797?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 11:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162227797","market":"sh","top_or_hot":-1,"title":"INNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026","media":"Stock News","content":"<p>Shares of <b>INNOGEN-B (02591)</b> have risen more than 6%. At the time of writing, the stock is up 5.79% to HK$10.62, with a turnover of HK$90.33 million.<br><br>The company has announced that it will present data from the Chinese Phase IIb clinical study of its drug, Esupaglutide α, at the American Diabetes Association (ADA) Scientific Sessions in 2026. This conference is scheduled to take place from June 5 to 8, 2026, in New Orleans, USA.<br><br>According to the announcement, the top-line results from the Phase IIb ENLIGHT study of INNOGEN's self-developed Esupaglutide α in Chinese patients with overweight/obesity have successfully met the primary endpoint. The randomized, double-blind, placebo-controlled, multicenter trial enrolled 200 adult subjects with overweight or obesity but without diabetes. It evaluated the efficacy and safety of Esupaglutide α at doses ranging from 5 mg to 20 mg over an 18-week treatment period.<br><br>The results indicated that all dose groups experienced significant weight reduction from baseline, outperforming the placebo group. The weight loss effect showed a positive correlation with the dose, and patients in the Esupaglutide α groups demonstrated a continuous downward trend in body weight throughout the treatment period, with no plateau observed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-03 11:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>INNOGEN-B (02591)</b> have risen more than 6%. At the time of writing, the stock is up 5.79% to HK$10.62, with a turnover of HK$90.33 million.<br><br>The company has announced that it will present data from the Chinese Phase IIb clinical study of its drug, Esupaglutide α, at the American Diabetes Association (ADA) Scientific Sessions in 2026. This conference is scheduled to take place from June 5 to 8, 2026, in New Orleans, USA.<br><br>According to the announcement, the top-line results from the Phase IIb ENLIGHT study of INNOGEN's self-developed Esupaglutide α in Chinese patients with overweight/obesity have successfully met the primary endpoint. The randomized, double-blind, placebo-controlled, multicenter trial enrolled 200 adult subjects with overweight or obesity but without diabetes. It evaluated the efficacy and safety of Esupaglutide α at doses ranging from 5 mg to 20 mg over an 18-week treatment period.<br><br>The results indicated that all dose groups experienced significant weight reduction from baseline, outperforming the placebo group. The weight loss effect showed a positive correlation with the dose, and patients in the Esupaglutide α groups demonstrated a continuous downward trend in body weight throughout the treatment period, with no plateau observed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1162227797","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162227797","pubTimestamp":1780456101,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of INNOGEN-B (02591) have risen more than 6%. At the time of writing, the stock is up 5.79% to HK$10.62, with a turnover of HK$90.33 million.The company has announced that it will present data...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","02591":"银诺医药-B","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"在ADA 2026关键临床数据展示之前，INNOGEN-B股价飙升超过6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1,"VXUS":1},"content_text":"Shares of INNOGEN-B (02591) have risen more than 6%. At the time of writing, the stock is up 5.79% to HK$10.62, with a turnover of HK$90.33 million.The company has announced that it will present data from the Chinese Phase IIb clinical study of its drug, Esupaglutide α, at the American Diabetes Association (ADA) Scientific Sessions in 2026. This conference is scheduled to take place from June 5 to 8, 2026, in New Orleans, USA.According to the announcement, the top-line results from the Phase IIb ENLIGHT study of INNOGEN's self-developed Esupaglutide α in Chinese patients with overweight/obesity have successfully met the primary endpoint. The randomized, double-blind, placebo-controlled, multicenter trial enrolled 200 adult subjects with overweight or obesity but without diabetes. It evaluated the efficacy and safety of Esupaglutide α at doses ranging from 5 mg to 20 mg over an 18-week treatment period.The results indicated that all dose groups experienced significant weight reduction from baseline, outperforming the placebo group. The weight loss effect showed a positive correlation with the dose, and patients in the Esupaglutide α groups demonstrated a continuous downward trend in body weight throughout the treatment period, with no plateau observed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162227797","isCrawlerRequest":true}